Literature DB >> 21595850

Tertiary hyperparathyroidism resistant to cinacalcet treatment.

Manabu Okada1, Yoshihiro Tominaga, Kumiko Izumi, Hironobu Nobata, Takayuki Yamamoto, Takahisa Hiramitsu, Makoto Tsujita, Norihiko Goto, Koji Nanmoku, Toshihiko Watarai, Kazuharu Uchida.   

Abstract

Cinacalcet hydrochloride (cinacalcet) has been reported to be efficacious for patients with tertiary hyperparathyroidism (THPT). We experienced five patients with THPT requiring parathyroidectomy (PTx) because of resistance to cinacalcet treatment and investigated their clinical characteristics and clinical course. The maximum diameter of the parathyroid gland estimated by ultrasonography before renal transplantation was evaluated. Serum total calcium, phosphorus, intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), and creatinine (Cr) levels were investigated every three months after the administration of cinacalcet and at PTx. After surgery, the Cr levels were followed. In all five patients, at least one parathyroid gland had a largest diameter of more than 1 cm, and the mean diameter was 18.7 mm (range 14.9-24.1 mm). Intact PTH and ALP levels gradually increased after the initiation of cinacalcet and the Cr levels transiently increased after PTx. These findings suggest that the existence of a severely enlarged nodular hyperplastic gland is a main factor involved in resistance to cinacalcet.
© 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595850     DOI: 10.1111/j.1744-9987.2011.00924.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  9 in total

Review 1.  Bone turnover in hyperparathyroidism.

Authors:  Katharina Kerschan-Schindl
Journal:  Wien Med Wochenschr       Date:  2012-07-18

2.  Unplanned 30-Day Readmissions after Parathyroidectomy in Patients with Chronic Kidney Disease: A Nationwide Analysis.

Authors:  Rocco Ferrandino; Scott Roof; Yue Ma; Lili Chan; Priti Poojary; Aparna Saha; Kinsuk Chauhan; Steven G Coca; Girish N Nadkarni; Marita S Teng
Journal:  Otolaryngol Head Neck Surg       Date:  2017-09-26       Impact factor: 3.497

3.  Association Between Resistance to Cinacalcet and Parathyroid Gland Hyperplasia in Kidney Transplant Recipients with Persistent Hypercalcemia.

Authors:  A Oruc; A Ersoy; A A Kocaeli; A Yildiz; O O Gul; E Ertürk; C Ersoy
Journal:  Int J Organ Transplant Med       Date:  2020

4.  Characteristics of Persistent Hyperparathyroidism After Renal Transplantation.

Authors:  Takayuki Yamamoto; Yoshihiro Tominaga; Manabu Okada; Takahisa Hiramitsu; Makoto Tsujita; Norihiko Goto; Shunji Narumi; Yoshihiko Watarai
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

5.  Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.

Authors:  Mark D Jäger; Michaela Serttas; Jan Beneke; Jörg A Müller; Harald Schrem; Alexander Kaltenborn; Wolf Ramackers; Bastian P Ringe; Jill Gwiasda; Wolfgang Tränkenschuh; Jürgen Klempnauer; Georg F W Scheumann
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

6.  Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report.

Authors:  Tsai-Sung Tai; Yueh-Han Hsu; Jia Ming Chang; Chien-Chin Chen
Journal:  BMC Endocr Disord       Date:  2019-01-28       Impact factor: 2.763

Review 7.  Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease.

Authors:  Joao F de Brito Galvao; Larry A Nagode; Patricia A Schenck; Dennis J Chew
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2013 Mar-Apr

8.  Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Authors:  Sohyun Jeong; In-Wha Kim; Kook-Hwan Oh; Nayoung Han; Kwon Wook Joo; Hyo Jin Kim; Jung Mi Oh
Journal:  Drug Des Devel Ther       Date:  2016-07-08       Impact factor: 4.162

9.  The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Jaruwan Ngamkam; Somratai Vadcharavivad; Nutthada Areepium; Titinun Auamnoy; Kullaya Takkavatakarn; Pisut Katavetin; Khajohn Tiranathanagul; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Sci Rep       Date:  2021-09-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.